Relmada Therapeutics (RLMD) Scheduled to Post Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect Relmada Therapeutics to post earnings of ($0.65) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. During the same quarter last year, the business posted ($0.84) earnings per share. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relmada Therapeutics Stock Performance

Shares of NASDAQ RLMD traded down $0.10 during mid-day trading on Tuesday, reaching $3.32. The company’s stock had a trading volume of 60,159 shares, compared to its average volume of 181,795. The stock has a 50-day moving average of $3.26 and a two-hundred day moving average of $3.30. Relmada Therapeutics has a 1-year low of $1.88 and a 1-year high of $7.22. The stock has a market capitalization of $100.16 million, a P/E ratio of -1.15 and a beta of 0.41.

Insider Buying and Selling

In related news, Director Charles J. Casamento acquired 13,000 shares of the stock in a transaction dated Monday, September 9th. The stock was purchased at an average cost of $2.56 per share, with a total value of $33,280.00. Following the completion of the purchase, the director now directly owns 13,000 shares in the company, valued at $33,280. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Relmada Therapeutics news, Director Charles J. Casamento bought 13,000 shares of the stock in a transaction dated Monday, September 9th. The stock was purchased at an average cost of $2.56 per share, for a total transaction of $33,280.00. Following the completion of the acquisition, the director now owns 13,000 shares of the company’s stock, valued at approximately $33,280. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Maged Shenouda bought 24,120 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was bought at an average cost of $2.95 per share, with a total value of $71,154.00. Following the transaction, the chief financial officer now owns 88,335 shares in the company, valued at $260,588.25. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 152,300 shares of company stock worth $429,655 in the last 90 days. Insiders own 18.00% of the company’s stock.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded Relmada Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the company from $3.50 to $13.00 in a research note on Tuesday, September 17th.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.